ArthritisSupport Email Bulletin
January 21st, 2000

In This Issue:

• Drug Applies to the FDA to be Considered Treatment for Early, Active Rheumatoid Arthritis
• Medical Centers Searching for Osteoarthritis Genes
• Researchers Identify Key Molecular Mechanism in Rheumatoid Arthritis
• Dramatic Advancement in Treating Juvenile Rheumatoid Arthritis
• When Arthritis Strikes

FEATURES

Drug Applies to the FDA to be Considered Treatment for Early, Active Rheumatoid Arthritis

Immunex Corporation announced today that the company has filed a supplemental biologics license application (sBLA) with the U.S. Food and Drug Administration (FDA) for Enbrel® (etanercept), seeking a new label for the drug to slow structural damage and to improve the signs and symptoms of early, active RA.

Go to:
http://www.arthritissupport.com/library/showarticle.cfm?id=47

Medical Centers Searching for Osteoarthritis Genes

It's not difficult to find a family in which generation after generation has struggled with the same inherited disease.

Go to:
http://www.arthritissupport.com/library/showarticle.cfm?id=48

Researchers Identify Key Molecular Mechanism in Rheumatoid Arthritis

A study at the University of North Carolina at Chapel Hill has identified a novel molecular mechanism in cell proliferation.

Dramatic Advancement in Treating Juvenile Rheumatoid Arthritis

A study conducted by researchers at Children's Hospital Medical Center of Cincinnati shows that nearly 75 percent of children with severe, longstanding juvenile rheumatoid arthritis (JRA) respond, often dramatically, to Enbrel (etanercept), a new drug.

When Arthritis Strikes

At least 10% of patients consulting a primary care physician have musculoskeletal complaints.